Teva Pharmaceuticals
TEVA
451 hedge funds and large institutions have $6.61B invested in Teva Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 130 increasing their positions, 140 reducing their positions, and 51 closing their positions.
75% more funds holding in top 10
Funds holding in top 10: 4 → 7 (+3)
20% more capital invested
Capital invested by funds: $5.52B → $6.61B (+$1.09B)
10% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 51
1% more call options, than puts
Call options by funds: $251M | Put options by funds: $249M
0% more funds holding
Funds holding: 450 → 451 (+1)
0.04% more ownership
Funds ownership: 52.24% → 52.29% (+0.04%)
7% less repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 140
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$54.5M |
| 2 |
MVP
Miller Value Partners
Sarasota,
Florida
|
+$39.2M |
| 3 |
PF
Phoenix Financial
Givatayim,
Israel
|
+$33.9M |
| 4 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
+$30.5M |
| 5 |
Legal & General Group
London,
United Kingdom
|
+$28.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$137M |
| 2 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
-$32.5M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$29.6M |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$28.2M |
| 5 |
O
OrbiMed
New York
|
-$18.7M |
TEVA Hedge Fund Activity: Q1 2021 in Review
451 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q1 2021, worth a combined $6.61B — up 20% from $5.52B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new TEVA positions and 51 closed out — a net gain of 5 holders — while 130 added to existing stakes and 140 trimmed.
The largest buyer was BlackRock, adding an estimated $54.5M. The largest seller was Capital International Investors, cutting an estimated $137M.
- 451 institutional investors held Teva Pharmaceuticals (TEVA) as of Q1 2021, up from 450 in Q4 2020.
- Funds reported $6.61B of Teva Pharmaceuticals stock for Q1 2021, up 20% quarter-over-quarter.
- 56 funds opened new Teva Pharmaceuticals positions in Q1 2021 and 51 closed out, a net change of +5 holders.
- The largest Teva Pharmaceuticals buyer in Q1 2021 was BlackRock, an estimated $54.5M added.
- The largest Teva Pharmaceuticals seller in Q1 2021 was Capital International Investors, an estimated $137M sold.
Based on aggregated 13F filings for Q1 2021.